biologic

Elitek

rasburicase

Loss of exclusivityJanuary 2018projected — 12-year biologic exclusivity estimate
CompanySanofi-Aventis U.S. LLC

Drug detail

Brand nameElitek
Active ingredientrasburicase
Strength7.5MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJanuary 2006
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Elitek patent cliff — loss of exclusivity January 2018 | CliffBio